JP2016502527A5 - - Google Patents

Download PDF

Info

Publication number
JP2016502527A5
JP2016502527A5 JP2015542832A JP2015542832A JP2016502527A5 JP 2016502527 A5 JP2016502527 A5 JP 2016502527A5 JP 2015542832 A JP2015542832 A JP 2015542832A JP 2015542832 A JP2015542832 A JP 2015542832A JP 2016502527 A5 JP2016502527 A5 JP 2016502527A5
Authority
JP
Japan
Prior art keywords
mir
hsa
composition
mirna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015542832A
Other languages
English (en)
Japanese (ja)
Other versions
JP6478916B2 (ja
JP2016502527A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/070350 external-priority patent/WO2014078686A1/en
Publication of JP2016502527A publication Critical patent/JP2016502527A/ja
Publication of JP2016502527A5 publication Critical patent/JP2016502527A5/ja
Application granted granted Critical
Publication of JP6478916B2 publication Critical patent/JP6478916B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015542832A 2012-11-16 2013-11-15 薬物耐性乳癌の予後判定および処置のための治療アジュバントおよびバイオマーカーとしてのｍｉＲＮＡ Expired - Fee Related JP6478916B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727481P 2012-11-16 2012-11-16
US61/727,481 2012-11-16
PCT/US2013/070350 WO2014078686A1 (en) 2012-11-16 2013-11-15 Mirnas as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers

Publications (3)

Publication Number Publication Date
JP2016502527A JP2016502527A (ja) 2016-01-28
JP2016502527A5 true JP2016502527A5 (https=) 2016-12-28
JP6478916B2 JP6478916B2 (ja) 2019-03-06

Family

ID=50731724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542832A Expired - Fee Related JP6478916B2 (ja) 2012-11-16 2013-11-15 薬物耐性乳癌の予後判定および処置のための治療アジュバントおよびバイオマーカーとしてのｍｉＲＮＡ

Country Status (6)

Country Link
US (2) US9730954B2 (https=)
EP (1) EP2919817A4 (https=)
JP (1) JP6478916B2 (https=)
CN (1) CN104884097B (https=)
CA (1) CA2930795A1 (https=)
WO (1) WO2014078686A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2686313C2 (ru) * 2015-02-25 2019-04-25 Байонир Корпорейшн Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента
CN106148538B (zh) * 2016-08-09 2019-10-22 山东大学 microRNA标志物组及其在制备评价乳腺癌化疗敏感性试剂盒中的应用
CN107970254A (zh) * 2017-12-08 2018-05-01 新乡医学院第附属医院 miR-204及其靶基因在诊断和治疗骨肉瘤中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5489459B2 (ja) * 2005-08-01 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物
JP2011516033A (ja) * 2008-02-28 2011-05-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 急性骨髄性性白血病（ａｍｌ）における細胞遺伝学および予後と関連するマイクロｒｎａシグネチャーおよびその使用
JP2011519951A (ja) * 2008-05-07 2011-07-14 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ｍｉＲＮＡによる薬物治療の増強
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer

Similar Documents

Publication Publication Date Title
Chen et al. A DNA/DMXAA/metal–organic framework activator of innate immunity for boosting anticancer immunity
Huang et al. Differential effects of extracellular vesicles from aging and young mesenchymal stem cells in acute lung injury
AU2018233032B2 (en) TEC family kinase inhibitor adjuvant therapy
Hu et al. Nanodrugs incorporating LDHA siRNA inhibit M2-like polarization of TAMs and amplify autophagy to assist oxaliplatin chemotherapy against colorectal cancer
Huang et al. An mTOR siRNA‐loaded spermidine/DNA tetrahedron nanoplatform with a synergistic anti‐inflammatory effect on acute lung injury
CN110934873B (zh) 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用
KR20160066554A (ko) 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료
KR20200104291A (ko) 항암제
Toro et al. New therapeutic perspectives in the treatment of uveal melanoma: a systematic review
Ye et al. GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways
CN106488766A (zh) 利用氧气疗法的分割放疗和化疗
AU2020322440A1 (en) Compositions and methods of using C/EBP alpha saRNA
Feng et al. Exploiting current understanding of hypoxia mediated tumour progression for nanotherapeutic development
Synoradzki et al. From molecular biology to novel immunotherapies and nanomedicine in uveal melanoma
Zhou et al. Tellurium/bovine serum albumin nanocomposites inducing the formation of stress granules in a protein kinase R-dependent manner
JP2016502527A5 (https=)
JP2009510165A5 (https=)
Luo et al. Genetically engineered biomimetic nanoparticles for synergistic activation of glioma-associated macrophages against glioblastoma
Lyu et al. Bispecific Antibody Targeting VEGF/TGF‐β Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal Effects
Cai et al. Plasma Extracellular Vesicle‐Derived miR‐296‐5p is a Maturation‐Dependent Rejuvenation Factor that Downregulates Inflammation and Improves Survival after Sepsis
US20240299356A1 (en) Development of prmt-targeting therapy to enhance egfr-targeting drug efficacy in nsclc
Huang et al. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced‐killer cells in a murine lung carcinoma model
US20200199681A1 (en) Mda-7 cancer therapies and methods of detecting biomolecules
Petrella et al. Stem cell technology for antitumor drug loading and delivery in oncology
Sastre-Garau Strumal carcinoid tumor of the ovary